3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Colorectal Neoplasms
33
Pancreatic Neoplasms
14
Neuroblastoma
12
Neoplasm Metastasis
10
Stomach Neoplasms
8
Neoplasms
8
Rectal Neoplasms
5
Small Cell Lung Carcinoma
4
Esophageal Squamous Cell Carcinoma
4
Colonic Neoplasms
4
Sarcoma, Ewing
3
Rhabdomyosarcoma
3
Ovarian Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma
3
Wilms Tumor
2
Sarcoma
2
Recurrence
2
Osteosarcoma
2
Gastrointestinal Neoplasms
2
Ganglioneuroblastoma
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Biliary Tract Neoplasms
2
Adenocarcinoma Of Esophagus
2
Uterine Neoplasms
1
Triple Negative Breast Neoplasms
1
Stage I Mixed Cell Type Kidney Wilms Tumor
1
Solid Tumors
1
Interventions
Carboplatin
4
pertuzumab
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Paclitaxel
2
Oxaliplatin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
talazoparib
1
sarilumab
1
relugolix
1
regorafenib
1
pexidartinib
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
nimotuzumab
1
neratinib
1
ganitumab
1
enzalutamide
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Pathologic Complete Response
×
Irinotecan
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled